| Trial ID: | L0962 |
| Source ID: | NCT00293202
|
| Associated Drug: |
Etanercept
|
| Title: |
Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00293202/results
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: Etanercept|DRUG: Placebo
|
| Outcome Measures: |
Primary: Albumin, An increased serum albumin (ALB) concentration expected. Higher concentrations of Albumin indicate better outcome. Normal ranges of Albumin in this study is from 3.5 to 5.5 gram per deciliter (g/dL). We expect ALB to remain or increase in this study., 52 weeks|C-reactive Protein, A reduced C-reactive protein (CRP) concentration is expected., 52 weeks | Secondary: Prealbumin (mg/dL), Effect of treatment on prealbumin (PAB) concentration, 52 weeks
|
| Sponsor/Collaborators: |
Sponsor: Kaysen, George A., M.D., Ph.D. | Collaborators: Amgen|Dialysis Clinic, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
10
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2005-01
|
| Completion Date: |
2010-06
|
| Results First Posted: |
2021-05-28
|
| Last Update Posted: |
2021-07-13
|
| Locations: |
University of California, Davis, Medical Center, Sacramento, California, 95817, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00293202
|
